28487075|t|N-(1H-Pyrazol-3-yl)quinazolin-4-amines as a novel class of casein kinase 1δ / ε inhibitors: Synthesis, biological evaluation and molecular modeling studies
28487075|a|Described herein is the design, synthesis and biological evaluation of a series of N-(1H-pyrazol-3-yl)quinazolin-4-amines against a panel of eight disease relevant protein kinases. The kinase inhibition results indicated that two compounds inhibited casein kinase 1δ / ε (CK1δ / ε) with some selectivity over related kinases, namely CDK5/p25, GSK-3α / β, and DYRK1A. Docking studies with 3c and 3d revealed the key interactions with desired amino acids in the ATP binding site of CK1δ. Furthermore, compound 3c also elicited selective cytotoxic activity against the pancreas ductal adenocarcinoma (PANC-1) cell line. Taken together, the results of this study establish N-(1H-pyrazol-3-yl)quinazolin-4-amines especially 3c and 3d as valuable lead molecules with great potential for CK1δ / ε inhibitor development targeting neurodegenerative disorders and cancer.
28487075	0	38	N-(1H-Pyrazol-3-yl)quinazolin-4-amines	T103	UMLS:C1254351
28487075	59	75	casein kinase 1δ	T103	UMLS:C1171766
28487075	78	79	ε	T103	UMLS:C0752519
28487075	80	90	inhibitors	T103	UMLS:C0243077
28487075	129	155	molecular modeling studies	T062	UMLS:C0600115
28487075	239	277	N-(1H-pyrazol-3-yl)quinazolin-4-amines	T103	UMLS:C1254351
28487075	303	310	disease	T038	UMLS:C0012634
28487075	320	335	protein kinases	T103	UMLS:C0033640
28487075	341	358	kinase inhibition	T038	UMLS:C2247121
28487075	367	376	indicated	T033	UMLS:C1444656
28487075	386	395	compounds	T103	UMLS:C1254351
28487075	406	422	casein kinase 1δ	T103	UMLS:C1171766
28487075	425	426	ε	T103	UMLS:C0752519
28487075	428	432	CK1δ	T103	UMLS:C1171766
28487075	435	436	ε	T103	UMLS:C0752519
28487075	473	480	kinases	T103	UMLS:C0033640
28487075	489	497	CDK5/p25	T103	UMLS:C0249586
28487075	499	505	GSK-3α	T103	UMLS:C3853562
28487075	508	509	β	T103	UMLS:C4283740
28487075	515	521	DYRK1A	T103	UMLS:C1453762
28487075	523	530	Docking	T038	UMLS:C1522290
28487075	531	538	studies	T058	UMLS:C0947630
28487075	544	546	3c	T103	UMLS:C1254351
28487075	551	553	3d	T103	UMLS:C1254351
28487075	597	608	amino acids	T103	UMLS:C0002520
28487075	616	619	ATP	T103	UMLS:C0001480
28487075	620	632	binding site	T038	UMLS:C1149343
28487075	636	640	CK1δ	T103	UMLS:C1171766
28487075	655	666	compound 3c	T103	UMLS:C1254351
28487075	722	752	pancreas ductal adenocarcinoma	T038	UMLS:C1335302
28487075	754	760	PANC-1	T038	UMLS:C1335302
28487075	762	771	cell line	T017	UMLS:C0085983
28487075	809	814	study	T062	UMLS:C2603343
28487075	825	863	N-(1H-pyrazol-3-yl)quinazolin-4-amines	T103	UMLS:C1254351
28487075	875	877	3c	T103	UMLS:C1254351
28487075	882	884	3d	T103	UMLS:C1254351
28487075	937	941	CK1δ	T103	UMLS:C1171766
28487075	944	945	ε	T103	UMLS:C0752519
28487075	946	955	inhibitor	T103	UMLS:C0243077
28487075	978	1005	neurodegenerative disorders	T038	UMLS:C0524851
28487075	1010	1016	cancer	T038	UMLS:C0006826